Risk for high blood pressure, kidney and cardiovascular disease can persist long after E. coli gastroenteritis

Research just published in the British Medical Journal presents another example of acute gastrointestinal infection triggering chronic inflammation that persists long after the infection has subsided. The authors set out to…

“…evaluate the risk for hypertension, renal impairment, and cardiovascular disease within eight years of gastroenteritis from drinking water contaminated with Escherichia coli O157:H7 and Campylobacter.”

They followed 1977 adult participants, 1067 of whom came down with acute gastroenteritis when a municipal water system was contaminated. None of them had a history of the subsequent diseases they were looking for which included hypertension (blood pressure ≥140/90 mm Hg), kidney impairment (microalbuminuria or estimated glomerular filtration rate <60 ml/min/1.73 m2), and cardiovascular disease (heart attack, stroke, or congestive heart failure). What did the data show?

“The adjusted hazard ratios for hypertension and cardiovascular disease after acute gastroenteritis were 1.33 and 2.13 respectively. The adjusted hazard ratio for the presence of either indicator of renal impairment was 1.15 and was 3.41 for the presence of both.”

In other words, having a case of acute gastroenteritis resulted in a later increase of 33% in the risk for high blood pressure, 213% for cardiovascular disease, and a whopping 341% for a combination of the two indicators of kidney impairment (microalbuminuria and lower glomerular filtration rate). Thus the authors conclude:

Acute gastroenteritis from drinking water contaminated with E coli O157:H7 and Campylobacter was associated with an increased risk for hypertension, renal impairment, and self reported cardiovascular disease…Our findings underline the need for following up individual cases of food or water poisoning by E coli O157:H7 to prevent or reduce silent progressive vascular injury…annual blood pressure monitoring and periodic monitoring of renal function may be warranted for individuals who experience acute gastroenteritis after exposure to food or water contaminated with E coli O157:H7.”

This is another example of how GI infections can trigger the long-term immune system dysregulation that promotes chronic inflammation, the biological basis of cardiovascular disease and renal impairment. Clinicians should be diligent in diagnosing GI infection and astute in examining for immune dysfunction and occult autoimmune disorders.

Beneficial E. coli helps heal ulcerative colitis

The emerging science of the human microbiome and modulation of the immune system by introducing specific strains of probiotic flora into the gut and other microbial ecosystems is one of the most fascinating and promising developments in medicine. A study published some time back in the journal GUT (An International Journal of Gastroenterology and Hepatology) is among a number of investigations into the benefit of Escherichia coli Nissle 1917 in stimulating the immune system to heal ulcerative colitis:

“We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis.”

The authors assigned 327 patients to receive either the Escherichia coli Nissle 1917 or mesalazine and evaluated the outcomes according to clinical, endoscopic  and histologic (tissue microscopic) indices over a twelve month period. Mesalazine is an anti-inflammatory medication administered by suppository that is not without concerns, and a suppressive palliation at best.

“The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses.”

Wouldn’t it be better to stimulate the immune system to express healthier regulation if possible? The data established this notable conclusion:

The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.”

This is but one example among many more you’ll be hearing about in this fascinating and promising area of research and clinical application.